PRA International Hosts Audio Conference on CV Drug Development

RALEIGH, N.C., Aug. 16 /PRNewswire/ -- PRA International, a leading Clinical Research Organization, will host an audio conference on strategies for successful cardiovascular (CV) drug development on 24 August 2010 at 11:30 am (EDT). Dr. Michael Kirchengast, Vice President and Head of PRA's Scientific Affairs unit, will be the presenter.

Dr. Kirchengast will discuss ways to prevent some of the expensive failures that pharmaceutical companies experience during late-stage CV drug development. The conference will review predictive pre-clinical models, innovative proof-of-concept designs in Phase IIa, cooperation among sponsors and regulatory agencies, and simpler protocols with similar endpoints throughout Phases II and III.

PRA's therapeutic expert in CV disease, Dr. Kirchengast has 30 years of experience in CV research and development, including interactions with multiple authorities. His wide range of development experience encompasses antiarrhythmics, antithrombotics, antihypertensives, antihyperlipidemics, heart failure therapeutics, and vascularly active and cardioprotective drugs.

PRA's Scientific Affairs group consists of strategic drug development professionals with expertise in medical informatics and investigator relations as well as therapeutic expertise in cardiovascular, oncology/hematology, infectious diseases, neurosciences, pediatrics, and respiratory medicine. The group combines in-house scientific expertise with hands-on pharmaceutical industry experience, guiding the development of drugs and biologics from the late preclinical phase to the marketing stage across PRA's core therapeutic areas.

For more information about this audio conference, navigate to www.praintl.com and click on "Events." To register, email [email protected]. The registration deadline is Monday, 23 August 2010.

About PRA International

PRA International conducts clinical trials in more than 85 countries across 6 continents and provides services through all phases of clinical development. PRA performs studies in all therapeutic areas, with specialization in Oncology, Neurosciences, Respiratory/Allergy, Cardiovascular and Infectious Diseases. In the last five years, PRA has supported over 2,700 clinical trials through its 38 global offices.

PRA's therapeutic expertise, global reach and project experience, combined with extensive local knowledge and our differentiating PERSONAL ELEMENT enable our project teams to deliver consistent and on time performance for our clients. This unique PRA philosophy - THE PERSONAL ELEMENT - recognizes that true client service comes only from trained, empowered and dedicated employees who are encouraged to use innovation and their personal commitment to accelerate the development lifecycle.

To learn more about PRA International, please visit www.PRAinternational.com, email [email protected] or call our Global Headquarters at +1 (919) 786-8200.

SOURCE PRA International

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED